MINDY1 and breast cancer: As MINDY1 was upregulated in ERα-positive breast cancer patients and associated with the ERα protein level, we then analyzed its prognostic value in ERα-positive breast cancer from GES6532, and observed that high expression of MINDY1 was associated with poor prognosis of patients with ERα-positive breast cancer (Fig. 2Q, R).